About the Study : Among adults with HIV at risk of treatment-associated weight gain, does an alternative first-line regimen produce less weight gain than treatment combinations containing an integrase strand transfer inhibitor (eg, dolutegravir or bictegravir) along with tenofovir alafenamide? In this noninferiority randomized clinical trial including 600 adults with HIV, initiating a regimen with doravirine, lamivudine, and tenofovir disoproxil fumarate was noninferior to a regimen with dolutegravir, emtricitabine, and tenofovir alafenamide for viral suppression (HIV RNA level <50 copies/mL) at 48 weeks (89.0% vs 90.7%, respectively, meeting the prespecified noninferiority margin of −10 percentage points), and was associated with less weight gain. Among adults initiating antiretroviral therapy, a regimen with doravirine, lamivudine, and tenofovir disoproxil fumarate was noninferior to a regimen with dolutegravir, emtricitabine, and tenofovir alafenamide for viral suppression at 48 weeks and was associated with less weight gain.
Meeting Information:
This paper will be presented at International Aids Society (IAS).
Corresponding Author : Joana Woods, MBChB, MPH, Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, 32 Princess of Wales Terr, Johannesburg, South Africa 2193 ( jwoods@ezintsha.org ).
10.1001/jama.2026.14762
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note : Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
JAMA